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There are some important prognostic factors for papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). In
this paper, clinicopathological features signiﬁcantly aﬀecting patient prognosis are described based on our data as well as others.
Distant metastasis at diagnosis is the most important prognostic factor for both PTC and FTC. Other than that, preoperative
and intraoperative ﬁndings are important to evaluate the biological behavior of PTC. Extrathyroid extension, large lymph-node
metastasis, and extranodal tumor extension that can be evaluated preoperatively or intraoperatively are signiﬁcant prognostic
factors for PTC patients. In contrast, pathological ﬁndings are important not only for diagnosis of FTC, but also for the evaluation
of its biological character. Grade of invasiveness (minimally or widely invasive) and degree of diﬀerentiation (well diﬀerentiated or
including a poorly diﬀerentiated component) greatly aﬀect the prognosis of FTC patients.
1.Introduction
There are two histological types of thyroid carcinoma arising
from follicular cells, which are papillary carcinoma (PTC)
and follicular carcinoma (FTC). These two histological types
are also called diﬀerentiated carcinoma (DTC) and analyzed
as a single group for clinical studies investigating prognos-
tic factors and prognosis of patients. However, biological
behaviors of these two carcinomas signiﬁcantly diﬀer. PTC
frequently metastasizes to the regional lymph nodes and can
showahighincidenceofsigniﬁcantextrathyroidextensionto
adjacent organs. In contrast, it is comparably rare for FTC to
show these events, but FTC more frequently metastasizes to
distant organs such as the lung, bone, and brain than PTC.
Therefore, analyses of prognostic factors and prognosis of
patients should be performed separately for PTC and FTC.
Generally, PTC and FTC are indolent diseases and show
good prognoses of patients, but when the lesion dediﬀer-
entiates, becoming undiﬀerentiated carcinoma (anaplastic
carcinoma), the prognosis of patients turned to be extremely
poor. The mechanism of dediﬀerentiation remains unknown
althoughthep53genemutationisfrequentlyobservedinUC
[1].
Inthe1980s,apathologicalentityofpoorlydiﬀerentiated
carcinoma (PDC) was proposed by Sakamoto et al. [2]a n d
Carcangiu et al. [3]. PDC implies thyroid carcinoma of
intermediate type between DTC and UC. It was adopted as
an independent histopathological category from PTC and
FTC in the WHO classiﬁcation [4]. However, as described
below, there are three kinds of diagnostic criteria for PDC
deﬁned in General Rules for the Description of Thyroid
Cancer established by Japanese Society of Thyroid Surgeons
(JSTS) [5], in WHO classiﬁcation [4], and in the Turin
proposal [6], which generates confusion among pathologists
and clinical physicians.
In this paper, we present the prognosis and prognostic
value of PTC and FTC together with PDC based on data
from Kuma Hospital as well as search results of studies from
other institutes. Since the traditional Japanese diet is iodine-
rich, the results may somewhat diﬀer from those in Western
countries.
2. Prognostic Factors of PTC
To date, several prognostic factors have been identiﬁed
for PTC. These factors can be divided into 4 categories,2 Journal of Thyroid Research
backgrounds of patients, factors based on preoperative, and
intraoperative and postoperative evaluations. Backgrounds
of patients include age, gender, and family history. Preop-
erative evaluation is mainly performed by imaging studies.
Of these, ultrasonography is the most useful tool to detect
and evaluate primary lesions [7]a n dr e g i o n a ll y m p hn o d e
metastasis except for metastasis to the mediastinal and
retropharyngeal nodes. In order to diagnose metastasis
to the upper mediastinal node and retropharyngeal node,
other imaging studies such as CT scan, MRI, and PET-
CT are useful. Ultrasonography cannot only detect thy-
roid nodules, but also qualitatively diagnose these nodes
based on the ﬁndings. Our institution diagnoses whether
thyroid nodules are malignant or benign based on our
own ultrasonographic grading system [7]. In association
with ultrasonography-guided ﬁne-needle aspiration biopsy
(FNAB), minute thyroid carcinoma, especially PTC, can
be diagnosed. Furthermore, size, location, and multiplicity
of primary lesions can be evaluated on ultrasonography.
Lymph node metastasis can also be diagnosed based on
ultrasonographic criteria. Among the systems available, the
criteria proposed by Antonelli et al. [8] are representative:
maximal diameter >1 c m ,c l e a rh y p o e c h o i cp a t t e r n ,a n d
rounded (shorter/longer diameter ratio > 0.7) or bulging
shapewithincreasedanteroposteriordiameter.Thesecriteria
arealmostthesameasthoseusedinourinstitutionexceptfor
maximal diameter >1cm. Ultrasonography-guided FNAB
andthyroglobulinmeasurementonwash-outofneedlesused
for FNAB [9] could be a great help to diagnose whether
the node is metastatic or reactive. Especially, it is useful
to diagnose whether clinical node metastasis in the lateral
compartment (level II–IV) is present and to decide whether
therapeutic modiﬁed radical neck dissection (MND) should
be performed.
Intraoperative evaluation is based on ﬁndings during
surgery, including extrathyroid extension and extranodal
tumor extension to adjacent organs. The degree of extension,
that is, to where and how the tumor extends, signiﬁcantly
aﬀects the prognosis of patients as described later.
Postoperative evaluation includes ﬁndings based on
pathological and molecular examinations. There are various
histological types in PTC, most of which are diagnosed on
pathological examination. Molecular examination includes,
for example, BRAF mutation analysis.
2.1. Prognostic Factors Related to Patient Backgrounds
2.1.1. Patient Age. Patient age is an important background
factor for predicting prognoses. Several classiﬁcation systems
have adopted age as a prominent factor in deciding whether
carcinoma should be considered high risk. For example,
AMES set the cutoﬀ a g ea t4 1f o rm a l e sa n d5 1f o rf e m a l e s
to discriminate between high-risk and low-risk patients [10].
UICC TNM classiﬁcation [11] and CIH classiﬁcation [12]
set the cutoﬀ age at 45 years and 50 years, respectively.
MACIS is a scoring system that also includes patient age as
a very signiﬁcant factor [13]. In our setting series, the cutoﬀ
age at 45 years aﬀected the cause-speciﬁc survival (CSS) of
patientstosomeextent,butitsprognosticimpactfordisease-
free survival (DFS) was weak [14] (Figures 1(a) and 1(b)).
Currently, we set the cutoﬀ age at 55 years, because this
mostsigniﬁcantlyreﬂectedpatientDFSandCSSinourseries
(Figures1(c)and1(d)).Onmultivariatestudy,ageat55years
or older was the most signiﬁcant prognostic factor for CSS,
except for distant metastasis at surgery [15].
2.1.2. Gender. Previous studies showed discrepant ﬁndings
regarding the prognostic value of gender [16–18]. In our
analysis of 6015 PTC patients, male gender was an indepen-
dent but moderate prognostic factor for DFS and CSS [15].
As indicated above, age and gender each independently
aﬀect patient prognosis. However, our recent data indicate
that the signiﬁcance of other prognostic factors varied
according to patient age and gender when analyzed in four
subsets of patients; older female, older male, younger female
and younger male. This issue will later be described brieﬂy as
an addendum.
2.1.3. Family History. PTC and FTC are generally considered
sporadic with the exception that these are lesions also
associatedwithrareinheriteddiseasessuchasfamilialadeno-
matous polyposis, Gardner syndrome, and Cowden disease
[19, 20]. However, case reports of DTC in monozygotic
twins and in a mother and son were published in 1955 and
1975,respectively,[21,22].Morerecently,populationstudies
showed that the risk of DTC was elevated in individuals
with a ﬁrst-degree relative having DTC [23, 24]. Although
the genes that cause these lesions have not been identiﬁed,
a deﬁnition of familial nonmedullary thyroid carcinoma
(FNMTC) has been established as patients with DTC having
one or more aﬀected persons among their ﬁrst-degree of
relatives [25]. It remains controversial whether FNMTC
shows a diﬀerent prognosis from sporadic DTC [26–30]. In
Japan, there are two studies investigating this issue in a large
series of patients [31, 32]. One study showed that FNMTC
was more likely to recur, but its CSS did not diﬀer from
that of sporadic DTC [31]. The other study demonstrated
that DFS and CSS of familial PTC did not diﬀer from
sporadic PTC [32] (Figures 2(a) and 2(b)). Interestingly,
the incidences of FNMTC in the two studies were similar
at about 5%. Currently, we have no evidence that familial
PTC shows a signiﬁcantly worse DFS than sporadic PTC or
that the therapeutic strategy should be changed. However,
familial PTC is more likely to be multiple, and recurrence
rate to the remnant thyroid, if total thyroidectomy is not
performed, is higher than that in patients with sporadic
lesions (5% versus 1%) [32]. Therefore, total thyroidectomy
is recommended for familial PTC patients regardless of
carcinoma stage.
2.2. Prognostic Factors Predominantly Based on
Preoperative Evaluation
2.2.1. Tumor Size. Tumor size was adopted as a factor
discriminating high-risk patients from others in various
classiﬁcation systems such as UICC classiﬁcation [11],Journal of Thyroid Research 3
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Figure 1: (a) Carcinoma recurrence (CR) rate of PTC patients aged 45 years or older and those younger than 45 years. (b) Carcinoma death
(CD) rates of PTC patients aged 45 years or older and those younger than 45 years. (c) CR rates of PTC patients aged 55 years or older and
those younger than 45 years. (d) CD rates of PTC patients aged 55 years or older and those younger than 45 years.
MACIS scoring system [13], and AMES [10]. In UICC TNM
classiﬁcation, there are two cutoﬀs, 2cm and 4cm (T1 for
2cm or less, T2 for 2.1–4cm, and T3 for larger than 4cm)
[11]. In AMES, 5cm is a cutoﬀ between high-risk and low-
risk patients [10].
Recently, an observation trial for PTC measuring 1cm or
less (microcarcinoma) without any high-risk features such
as clinical lymph node and/or distant metastasis has been
performed in some institutions in Japan [33–37]. In our
data,onlyabout7%oflow-riskmicrocarcinomasigniﬁcantly
enlarged during followup once or twice per year for 5 years,
and none of these patients showed recurrence or died of
carcinoma after surgery at the appearance of progression
signs such as tumor enlargement and newly detected lymph
node metastasis. In Japan, therefore, cutoﬀ at 1cm was con-
sidered important and General Rules for the Description of
Thyroid Cancer established by JSTS further divided T1 into
two categories, T1a (1cm or less) and T1b (1.1–2cm) [5].
Previous autopsy studies demonstrated that small thyroid
carcinoma was detected with a signiﬁcantly high incidence
[38–40]. Furthermore, thyroid carcinomas were detected
in 3.5% of otherwise healthy Japanese women aged 30
years or older using ultrasonography and ultrasonography-
guided FNAB [41]. Thus, it is suggested that most small
thyroid carcinomas remain latent and do not or only very
slowly grow. The successful results of an observation trial of
microcarcinoma indicated that the above should, therefore,
be reasonable.4 Journal of Thyroid Research
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Figure 2: (a) CR rates of familial and sporadic PTC patients.
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Figure 3: Lymph-node recurrence rates of PTC patients having
tumors larger than 3cm and those having tumors measuring 3cm
or less.
In contrast, in our data based on a series of patients
treated in our institution, tumor size larger than 4cm
signiﬁcantly aﬀected DFS and CSS of PTC patients on
multivariate analysis [15]. Therefore, careful and extensive
surgery and postoperative followup are recommended for
PTC patients larger than 4cm even though there are no
other high-risk features. Furthermore, 10-year lymph-node
recurrence rates of N0 or N1a PTC patients having tumors
larger than 3cm were higher at 13% than that of those
measuring 3cm or less, which was 3% even though patients
underwent central node dissection and prophylactic MND
[42]( Figure 3). If prophylactic MND were not performed,
lymph-node recurrence rate would be even higher for N0
or N1a PTC larger than 3cm. Based on these data, our
institution performs prophylactic MND for N0 or N1a PTC
withatumorlargerthan3cm.Sugitanietal.alsoshowedthat
PTC larger than 4cm should be indicated for prophylactic
MND [43].
2.2.2. Multiplicity of Primary Lesions. PTC is frequently mul-
tiple. We previously showed that lateral node metastasis is
more frequently detected in multiple microcarcinomas than
in solitary microcarcinomas [34]. It is, therefore, suggested
that multiplicity reﬂects the aggressive behavior of PTC to
some extent. However, in our study analyzing over 6000
patients with PTC, multiplicity was not an independent
prognostic factor on multivariate analysis [14].
ThereisalimitationindiagnosingmultiplicityofPTCon
ultrasonography. Our data on microcarcinoma demonstrat-
ed that the diagnostic accuracies of ultrasonography for
multiplicity were 53% for sensitivity and 85% for speciﬁcity
[14]. This indicates that preoperative evaluation on ultra-
sonographyoftenoverlooksmultiplicityofcarcinoma,which
is one of the reasons for almost routine recommendation
of total thyroidectomy for PTC patients. However, our in-
stitution generally performs hemithyroidectomy for patients
with PTC measuring 2cm or smaller (T1 in UICC TNM cl-
assiﬁcation)diagnosedassolitaryonultrasonography,unless
they have clinical lymph node or distant metastasis or family
histories. The 10-year carcinoma recurrence rate was only
5% for these patients (Figure 4(a)). The risk of recurrence
to the remnant thyroid was only 1% for patients who un-
derwent limited thyroidectomy, and, if this risk is ignored,
the extent of thyroidectomy did not aﬀect patient prognosis
(Figure 4(b))[ 44]. Even though tiny PTC lesions remain un-
dissected, these lesions are generally harmless for such low-
risk patients. Therefore, we currently conclude that total thy-
roidectomy is not mandatory for solitary T1N0M0 patients.
2.2.3. Clinical Lymph Node Metastasis (N). Lymph node
metastasis is a very common event and recognized as one of
the most important prognostic factors. However, prominent
classiﬁcation systems such as AMES [10] and MACIS [13]d o
not adopt lymph-node metastasis as a prognostic factor. This
may be possibly because these systems were based on a series
of patients who underwent surgery before the establishment
of routine ultrasonography as a preoperative imaging study
for accurate evaluation of lymph-node metastasis.Journal of Thyroid Research 5
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Figure 5: CR rates of N0, N1a, and N1b PTC patients without extrathyroid extension.
At present, lymph-node metastasis can be preoperatively
evaluated on imaging studies, and, as indicated above,
ultrasonography is the most useful tool for this purpose.
Node metastasis detected on preoperative imaging studies is
called clinical lymph node metastasis (N), which is discussed
in this section. Similar to multiplicity, ultrasonography
often overlooks lymph-node metastasis, which can only be
diagnosed on postoperative pathological examination in a
large number of cases, as described later.
Evaluation of clinical node metastasis is very important,
and it was divided into two categories in UICC TNM classiﬁ-
cation[11]:N1a,centralnodemetastasisandN1b,metastasis
to the lateral or mediastinal compartment. In this classiﬁca-
tion,N1bisupgradedcomparedtoN1aandN1bpatientsare
further upstaged if they are aged 45 years or older.
Indeed, N has an important prognostic impact. We
previously showed that N1b was an independent prognostic
factor aﬀecting both DFS and CSS [33, 45–49]. However,
more recently, we also demonstrated that in the subset of
patients without signiﬁcant extrathyroid extension, progno-
sis of patients with N1b did not much diﬀer from that of
N1a patients although it was signiﬁcantly worse than N0
patients [50] (Figures 5(a) and 5(b)). Therefore, it remains
unclear whether it is appropriate to upgrade N1b compared
with N1a. Importantly, CIH classiﬁcation adopted lymph-
node metastasis measuring 3cm or larger as a factor of high
risk [11]. We analyzed this issue in our series and obtained
similar results [50]. In the same series, we also found that
extranodal tumor extension to adjacent organs requiring the
dissection of these organs that was predominantly evaluated6 Journal of Thyroid Research
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Figure 6: CR rates of PTC patients with low risk, intermediate risk, and high risk for lymph-node metastasis.
on intraoperative ﬁndings had a signiﬁcant prognostic value
especially for CSS as indicated below [14, 50, 51].
Taken together, it is currently considered that the prog-
nostic impact of clinical node metastasis can be divided
into three categories: (1) clinical node metastasis measuring
3cm or larger or showing extranodal tumor extension on
intraoperative ﬁndings (high risk), (2) clinical node metas-
tasis smaller than 3cm without extranodal tumor extension
(intermediate risk), and (3) no clinical node metastasis (low-
risk). Figures 6(a) and 6(b) indicate carcinoma recurrence
rate and carcinoma death rate of three categories for
carcinoma recurrence rate and carcinoma death rate.
2.2.4. Distant Metastasis at Surgery (M1). Although rarer
than FTC, PTC can metastasize not only to regional lymph
nodes, but also to distant organs such as the lung, bone,
and brain. Distant metastasis at surgery can be detected on
imaging studies such as CT scan and PET-CT and also on
postoperative radioactive iodine (RAI) ablation or whole
body scan.
There are no doubts that distant metastasis at surgery
is one of the most important prognostic factors for CSS
of patients [14]. However, prognosis of M1 patients diﬀers
accordingtootherclinicopathological featuresof thepatient.
Many previous studies analyzed M1 patients and patients
showing distant recurrence during postoperative followup
as a single group and/or analyzed PTC and FTC as DTC
in a single group [52–55]. In our opinion, these should be
separately analyzed as described in the Introduction. In the
subset of M1 patients with PTC in our series, M1 is directly
linked to other clinicopathological features such as gender,
tumor size, extrathyroid extension, and N factor, indicating
that distant metastasis at diagnosis will more likely be found
in PTC showing aggressive behavior [56]. Tumor larger than
4cm, aged 55 years or older (at the time of initial surgery)
and extrathyroid extension were independent prognostic
factors for CSS of M1 PTC patients (Figures 7(a), 7(b),
and 7(c)). Distant metastasis to organs other than the lung
also reﬂected worse CSS of patients on univariate analysis.
Furthermore, although there was no signiﬁcant diﬀerence,
CSS of M1 patients whose distant metastases were refractory
to RAI therapy was also adverse.
Taken together, the prognosis of M1 patients depends on
clinicopathological features of the primary lesion.
2.3. Prognostic Factors Predominantly Based on
Intraoperative Findings
2.3.1. Extrathyroid Extension. Extrathyroid extension has
been adopted in various classiﬁcation systems [10–13]. In
the UICC TNM classiﬁcation system, there are two grades of
extrathyroid extension [11]. Extension to perithyroid tissue
and sternothyroid muscle was graded as T3 (minimal exten-
sion), and extension to other adjacent organs such as the
recurrent laryngeal nerve, esophagus, trachea, sternohyoid
muscle, and jugular vein was graded as T4 (massive or
signiﬁcant extension). However, this classiﬁcation has some
limitations. Firstly, this classiﬁcation system is established
for preoperative evaluation. However, it is signiﬁcantly
diﬃcult to accurately evaluate extrathyroid extension based
on preoperative evaluation unless recurrent laryngeal nerve
paralysis due to carcinoma invasion and apparent intratra-
cheal extension on CT scan or MRI can be detected. Most
extrathyroid extensions are found on intraoperative ﬁnd-
ings, indicating that T classiﬁcation based on preoperative
ﬁndings is not appropriate. It is almost impossible to detect
T3 based on preoperative ﬁndings and evaluation of T4 on
preoperative ﬁndings is also much more inaccurate than that
on intraoperative ﬁndings. Secondly, our previous studies
showed that T3 did not aﬀect patient prognosis either on
intraoperative or pathological evaluation [57, 58]. In UICCJournal of Thyroid Research 7
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TNM classiﬁcation, tumors measuring 4 cm or less are
upgraded to T3 if they showed minimal extension, but we
proposed that such an upgrade should be abolished based
on our data. In our institution, only significant extrathyroid
extension on intraoperative ﬁndings is adopted as a factor
indicating aggressive behavior.
Our recent study showed that the signiﬁcance of extra-
thyroid extension is not uniform but rather size-dependent.
Prognostic signiﬁcance of extrathyroid extension was less
than clinical lateral node metastasis (N1b) for PTC measur-
ing 3cm or less, it was reversed in PTC larger than 3cm
[59]. In the intraoperative staging system that we established
by revising the UICC TNM staging system, extrathyroid ex-
tension of tumor larger than 2cm was regarded as a sign of
high risk and that of a tumor 2cm or smaller was a sign of
intermediate risk [14].
We currently conclude that extrathyroid extension
should be evaluated on intraoperative ﬁndings and that
minimal extension to perithyroid tissue and the sternothy-
roid muscle should not be considered signiﬁcant. Signiﬁcant
extension on intraoperative evaluation is an important
factor predicting a worse prognosis for patients with PTC,
especially those with a large tumor.
2.3.2. Extranodal Tumor Extension. Prognostic signiﬁcance
of extranodal tumor extension has been investigated by
several groups including ours [14, 50, 51, 60–62]. Yamashita
et al. showed that patients with pathological extranodal
tumor extension were more likely to show distant recurrence
[61]. In our series, as indicated above, extranodal tumor
extension requiring resection of adjacent organs showed a
worse prognosis, especially for CSS as indicated above [14,
50, 51]. It is strongly suggested that PTC with extranodal
tumor extension is high risk and has a high potential to show
a dire prognosis.8 Journal of Thyroid Research
2.4. Prognostic Factors Based on Postoperative Findings
2.4.1. Pathological Lymph-Node Metastasis. PTC frequently
metastasizes to the regional lymph nodes [63–65]. As
indicated above, clinical lymph-node metastasis detected
on preoperative imaging studies is a signiﬁcant prognostic
factor, and especially, large metastatic node has a very
strong prognostic impact on both DFS and CSS of PTC
patients. However, diagnostic accuracy of ultrasonography
for lymph-node metastasis is actually not very high. Our
previous study showed that the positive predictive value
(PPV) and speciﬁcity of ultrasonography for central node
metastasis were 92% and 98%, respectively, but the negative
predictive value (NPV) and sensitivity were only 37% and
12%, respectively, [15]. For lateral node metastasis, PPV and
speciﬁcity were 95% and 97%, respectively, and NPV and
sensitivity were 43% and 29%, respectively, [15]. Diagnostic
accuracy of ultrasonography for lateral node metastasis is
a little better than that for central node metastasis, but
these ﬁndings indicate that small and latent metastasis
to the regional lymph nodes is frequently overlooked on
ultrasonography. However, according to our data, such
latent metastases do not markedly aﬀect patient prognosis.
Pathological and latent node metastases increase the rate of
carcinoma recurrence to some extent but do not aﬀect CSS
of patients [32, 45]. In conclusion, lymph-node metastasis
that can be diagnosed only on pathological examination is a
moderate factor only for PTC recurrence.
2.4.2. Histological Variants. Many histological variants of
PTC have been adopted in the WHO classiﬁcation [4].
Table 1 summarizes the prevalence of histological variants
in our series of 1521 PTC patients [66]. Follicular variant
was the most common variant, which accounted for 7%.
Follicular variant was reported to show aggressive behavior
[67–69], but in our series of Japanese patients, prognosis
did not diﬀer from that of conventional PTC [66]. Tall cell
variant is a typical variant showing an aggressive behavior
[70–72] (Figures 8(a) and 8(b)). This accounted for 4% of
our series of PTC patients [73]. Interestingly, the incidence
ofclinicopathologicalfeaturesreﬂectingpoorprognosissuch
as gender, clinical lymph-node metastasis, and extrathyroid
extension did not diﬀer between tall cell variant and others
although the average age of patients with tall cell variant
was slightly higher than that of other patients. However,
this histology independently aﬀected DFS and CSS of PTC
patients on multivariate analysis [73]. Oncocytic variant
accounted for 2% of PTC and most of them were diagnosed
as having Warthin-like tumor showing abundant chronic
inﬂammatory cells that are associated with chronic thyroidi-
tis. Previous studies showed that this variant generally had a
mild character [74–76], which was identical to our ﬁndings,
because none of the patients with this oncocytic variant died
of carcinoma in our study [66].
There are some more important variants of which pre-
valence is lower than those indicated above. Columnar
cell variant is now classiﬁed as an independent entity as
columnar cell carcinoma [4]. This carcinoma accounted
o n l yf o r0 . 4 % ,b u ta sm u c ha s6 0 %o fp a t i e n t ss h o w e d
Table 1: Prevalence of conventional and various histologic variants
in 1521 papillary carcinomas.
Conventional 86%
Follicular variant 7%
Tall cell variant 4%
Oncocytic variant 2%
Columnar cell variant 0.4%
Macrofollicular variant 0.3%
Diﬀuse sclerosing variant 0.3%
Cribriform morular variant 0.1%
Others 0.1%
carcinoma recurrence, indicating that this histologic type is
a sign of signiﬁcantly aggressive behavior [66]. Regarding the
biological behavior and prognosis of the diﬀuse sclerosing
variant, previous studies showed discrepant ﬁndings [77–
79]. In our study, the diﬀuse sclerosing variant frequently
showedmultipleclinicalnodemetastasesandwasmorelikely
to show PTC recurrence, but the CSS of patients did not
diﬀer from that of conventional PTC [80]. Macrofollicular
variant could be diagnosed as multinodular goiter in the past
in high incidences [81,82]. Inourstudy, itshowsanindolent
character, similar to reports from Western countries [83].
Cribriform morular variant is mostly a hereditary disease
caused by the APC gene mutations associated with colonic
polyposis or colon carcinoma [84]. This variant is multi-
centric and total thyroidectomy is mandatory regardless of
carcinoma size and lymph-node status, but the prognosis of
patients is generally excellent [85].
Although not adopted in the WHO classiﬁcation, encap-
sulated, PTC generally shows a better prognosis than con-
ventional PTC. This type is encapsulated and there is no
extrathyroidextension,whichmaybethereasonforexcellent
prognosis. The incidence of lymph-node metastasis is also
lower than that in conventional PTC [86, 87].
2.4.3. Involvement of PDC Components. As indicated in
Section 1, three criteria for PDC have been proposed. There
are three growth patterns of PDC, solid, trabecular, and
insular growth patterns, which are designated as PDC
components. In order to diagnose PDC using the WHO
classiﬁcation, PDC components should occupy in the major-
ity of the tumor [4]. However, in the JSTS criteria [5],
carcinoma with only a small portion of PDC components is
diagnosed as PDC and discriminated from PTC or FTC. In
the criteria for PDC in the Turin proposal [6], the absence
of nuclear features of PTC and the presence of convoluted
nuclei, mitotic activity (3×10HPF), or tumor necrosis were
adopted in addition to the presence of a PDC component.
At present, PDC is considered as an independent entity
from PTC and FTC in WHO classiﬁcation [4]a n dJ S T S[ 5],
and it may be better to describe PDC in an independent
chapter. However, the diagnostic criteria for PDC have not
yet been consolidated. Thus, in this paper, the involvement
of PDC components is regarded as one of the pathological
features of both PTC and FTC.Journal of Thyroid Research 9
Years after surgery
0
20
40
60
80
100
C
R
r
a
t
e
s
(
%
)
0 5 10 15 20
P = 0.0001
Tall cell (59 patients)
Conventional (1297 patients)
(a)
0
20
40
60
80
100
0 5 10 15 20
Years after surgery
P = 0.0008
Tall cell (60 patients)
Conventional (1313 patients)
C
D
r
a
t
e
s
(
%
)
(b)
Figure 8: CR rates of tall cell variant and conventional PTC.
Actually, few studies have been published regarding
the prevalence of PDC based on all three criteria in one
series of patients. In our series, the prevalences of PDC
based on JSTS guidelines, the WHO classiﬁcation, and the
Turin proposal were 11%, 0.8%, and 0.3%, respectively,
in our PTC series [73]. This suggests that, in most cases,
PDC components are present only in a small portion of
carcinoma lesions. In our series, the 10-year DFS rates of
PTC with and without PDC components were 88.8% and
77.0%, respectively, and the CSS rates were 94.2% and
98.4%, respectively. On multivariate analysis, the presence
of PDC components independently reﬂected DFS but not
CSS of patients. Based on these ﬁndings, it does not seem
appropriate for PTC with limited PDC components (PDC
on JSTS) to be classiﬁed as an independent entity. A recent
study from Japan, however, demonstrated that DTC having a
PDC component comprising 10% or more of the carcinoma
lesion had a dire prognosis [88] and publications from
other institutions are expected to elucidate this issue. In
our series, the 10-year DFS and CSS rates of patients with
PDC according to the WHO classiﬁcation were 54% and
80%, respectively, and it is considered reasonable to regard
this carcinoma as an independent entity. Patient with PDC
according to the Turin proposal accounted for only 0.3%
in this series, and the 10-year DFS and CSS were 25% and
60%, respectively. This carcinoma has a signiﬁcantly more
aggressive character, but in Japan, the incidence is very small
compared with that in Europe and the United States [89, 90].
2.4.4. Cell Proliferating Activity. Cell proliferating activity
is regarded as an important biological behavior of human
carcinoma. There are some markers for evaluation of cell
proliferating activity, mitotic ﬁgure count (MFC), prolif-
erating cell nuclear antigen (PCNA), and Ki-67. In PTC,
however, cell proliferating activity is generally low. MFC
that is evaluated on hematoxylin and eosin-stained tissue
sections reﬂects only the index of mitotic cells, indicating
that it is diﬃcult to evaluate in PTC [91]. PCNA and Ki-
67 can be evaluated by immunohistochemistry. The former
is a cell cycle-related protein showing an elevated expression
level in cells exclusively in the G1-S phase [92]. Ki-67 is a
protein expressed in the cell nuclei in all cells except those
in the G0 phase [93]. Therefore, labeling index (LI) of PCNA
shouldbesmallerthanKi-67LI,butpreviousstudiesshowed
that PCNA LI was generally higher than Ki-67 LI [94, 95].
Furthermore, PCNA LI were reported not to correlate with
Ki-67 LI or MFC [94], indicating that PCNA is an unreliable
marker for evaluation of cell proliferating activity.
Therefore, it is concluded that Ki-67 LI is the most useful
marker for evaluation of cell proliferating activity for PTC.
Interpretation of Ki-67 LI data varies according to the origin
of carcinoma, but counting Ki-67 LI in hot spots is generally
accepted for PTC, because Ki-67 LI in PTC is mostly low.
Previous reports examined Ki-67 LI in specimens obtained
from FNAB and found that Ki-67 LI ≥ 4% predicted a
worse CSS [96]. However, FNAB specimens are not always
collected from hot spots, indicating that FNAB specimens
with low Ki-67 LI do not always reﬂect low proliferating
activityofPTCtissue.Inourpreviousstudy,Ki-67LIdirectly
related to extrathyroid extension, patient age, and distant
metastasis at surgery [97]. Furthermore, Ki-67 LI > 1% and
>3% were independent prognostic factors for DFS and CSS,
respectively,(Figures9(a)and 9(b)).Theoptimal cutoﬀof LI
should be determined in each institution, but PTC with high
Ki-67 LI should be carefully followed.
2.4.5. BRAF Gene Mutation. BRAF is a Raf kinase and
a potent activator of the MAPK pathway contributing
largely to cell proliferation, apoptosis, survival, and tumori-
genesis [98–100]. BRAF mutation has been detected in
various human malignancies and the hot-spot mutation
is a thymine-to-adenine transversion at nucleotide 1799
(T1799A)onexon15,resultinginavaline-to-glutamatesub-
stitutionatresidue600(V600E)[101].Inthyroidcarcinoma,
studies for BRAF mutation have been actively performed.10 Journal of Thyroid Research
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Figure 9: CR rates of PTC patients with Ki-67 1% or less, 1.1–3%, 3.1–5%, and greater than 5%.
This event was exclusively detected in PTC and its prevalence
ranged from 28% to 83% [102–109]. Reports from Western
countries and some Asian countries demonstrated that the
prognosis of PTC with BRAF mutation was signiﬁcantly
worse than that with no mutation [102, 103, 105–109].
In our data analyzing 631 patients, however, BRAF
mutation was not linked to any clinicopathological features
of PTC patients or aﬀected prognosis of patients even on
univariate analysis [110]. Its prevalence varies according to
histology, and it was higher in tall cell variant and lower in
follicular variant than in conventional PTC, which was not
discrepant with previous studies [111, 112].
Although there seems to be a consensus that BRAF
mutation signiﬁcantly reﬂects an aggressive character in PTC
in Western countries and some Asian countries, its role
remains unclear in Japan, because there have not been any
other studies in a large number of patients with long-term
followup, to date.
2.5. Discussion and Summary. Due to the prevalence of
ultrasonography-guided FNAB, most PTC can be diagnosed
before surgery. There are several important prognostic
factors for PTC based on patient backgrounds and ﬁndings
on preoperative imaging studies. Furthermore, some prog-
nostic factors are evaluated based on intraoperative ﬁndings.
Therefore, the biological behavior, including prognosis of
patients, of PTC can generally be evaluated before the end
of surgery. Pathological evaluation is less signiﬁcant than
preoperative and intraoperative evaluations, but it is still
important to diagnose certain variants and the involvement
of PDC components, both of which aﬀect patient prognoses.
Based on the series in our study, the important prog-
nostic factors of PTC patients are age 55 years or older,
distant metastasis at surgery, clinical lymph-node metastasis
measuring 3cm or larger, extranodal tumor extension, and
signiﬁcant extrathyroid extension (especially for large PTC,
e.g., larger than 2cm). Tumor larger than 4cm, clinical
node metastasis smaller than 3cm with no extranodal
tumor extension, and male gender are moderate prognostic
factors. Latent node metastasis detected only on pathological
examination and multicentricity can be prognostic factors
but the impact of these is low.
Apart from the above, there are some important patho-
logical ﬁndings aﬀecting prognosis. Tall cell variant, colum-
nar cell variant, and involvement of PDC components in the
majority of the carcinoma lesion are signiﬁcant prognostic
factors on pathological examination. High Ki-67 LI might
be a predictor of a dire prognosis. Presence of limited
PDC components is also a moderate to weak prognostic
factor, because it predicts a worse DFS but not CSS. Table 2
summarizes the risk factors of PTC based on preoperative,
intraoperative and pathological evaluations.
3. Prognostic Factors of FTC
FTC is only occasionally diagnosed on preoperative cytology,
which is in sharp contrast to PTC. Most patients with
FTC undergo hemithyroidectomy based on the preoperative
diagnosis as follicular tumor or adenomatous nodules. Gen-
erally, patients are diagnosed as having FTC on postoperative
pathological examination. FTC is less likely to metastasize
to the regional lymph node and lymph-node dissection
is rarely performed in surgery for patients suspected of
FTC. Extrathyroid extension is also a rare event and in our
series, only 2% of patients showed an extension to adjacent
organs [113]. Therefore, prognostic factors of FTC based on
preoperative ﬁndings were less signiﬁcant than those of PTC.
3.1. Prognostic Factors Based on Patient Backgrounds
3.1.1. Patient Age. Patient age has been adopted as a sig-
niﬁcant prognostic factor for FTC [114–119]. In our series ofJournal of Thyroid Research 11
Table 2: Risk classiﬁcation of TPC based on preoperative, intraoperative, and pathological ﬁndings.
High risk
(a) Patients having distant metastasis at presentation.
(b) Patients including PDC components in majority of carcinoma lesions.
(c) Patients diagnosed as tall cell variant.
(d) Patients 55 yrs or older and having one of the following three:
(1) tumor size >2 cm with extension to adjacent organs, (corresponding to T4),
(2) lymph-node metastasis >3c m ,
(3) lymph-node metastasis extending to adjacent organs
Intermediate risk
(a) Patients including PDC component in small portion of carcinoma lesions.
(b) Patients 55 yrs or older and having one of the following three:
(1) tumor size >4cm (excluding T4 cases),
(2) tumor size ≤2cm with extension to adjacent organs (corresponding to T4),
(3) lymph-node metastasis detectable on preoperative imaging studies ≤3cm and without extension to adjacent organs
Low risk
(a) Patients under 55 yrs without distant metastasis at diagnosis.
(b) Patients 55 yrs or older who are not classiﬁed as high risk or intermediate risk
334 patients, age 45 years or older had a prognostic impact
for CSS on univariate analysis but was not an independent
prognostic factor [113]. Interestingly, in contrast to PTC, age
cutoﬀ at 45 years had the strongest prognostic impact in our
series.
3.1.2. Gender. Some previous studies demonstrated the pro-
g n o s t i ci m p a c to fg e n d e ro fF T Cp a t i e n t s[ 16, 119, 120]. In
our series, male patients tended to show recurrence only on
univariate analysis (Figure 10). However, male gender did
not show any prognostic impact on CSS of patients.
3.2. Prognostic Factors Based on Preoperative Evaluation
3.2.1. Clinical Lymph-Node Metastasis. S i n c ei ti sr a r ef o r
FTCtoshowclinicallyapparentnodemetastasis,itisdiﬃcult
to evaluate its prognostic value. However, as indicated below,
we demonstrated that 10 of 11 patients showing pathological
nodemetastasisshowedanaggressivepathologysuchasPDC
or widely invasive carcinoma [113], indicating that FTC with
clinically apparent node metastasis is progressive and shows
an aggressive behavior.
3.2.2. Distant Metastasis at Surgery. Undoubtedly, this is an
important prognostic factor as shown in previous studies
including ours [16, 113–122]. Five-year CSS of patients with
distant metastasis at surgery was around 55% in our series
[113]. Distant metastasis at surgery was directly linked to
age 45 years or older, lymph-node metastasis, invasive grade,
and poor diﬀerentiation in our series. For CSS, distant
metastasis at surgery or locally palliative surgery was the
most important prognostic factor on multivariate analysis.
3.2.3. Tumor Size. Relationship between tumor size and
prognosis has been reported [120, 121]. We previously
demonstrated that tumor larger than 4cm aﬀected both DFS
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Figure 10: CR rates of female and male FTC patients.
and CSS patients on univariate analysis. On multivariate
analysis, tumor size had a marginal signiﬁcance for DFS, but
not for CSS.
3.2.4. Family History. Familial FTC accounted for 1.4% of
FTCinJapan,butprognosisofthesecasesdidnotdiﬀerfrom
that of FTC with no family history [123]. To date, there have
not been any other reports regarding this issue.
3.3. Prognostic Factors Based on Intraoperative Findings
3.3.1. Extrathyroid Extension. As indicated above, extrathy-
roid extension is a rare event for FTC in Japan. In our
series, all patients who showed extrathyroid extension were
diagnosed as having PDC components [113]. It is, there-
fore,suggested that extrathyroid extension is an unusual
event for FTC but predicts an adverse prognosis.12 Journal of Thyroid Research
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Figure 11: CR rates of minimally and widely invasive FTC.
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Figure 12: CR rates of FTC patients with and without PDC components.
3.4. Prognostic Factors Based on Pathological Examination
3.4.1.DegreeofInvasiveness. FTCispathologicallydiagnosed
when it shows capsular and/or vascular invasion of tumor
cells. FTC is divided into two categories: (1) minimally
invasive FTC, small number of invasive sites can be only
histologically detected and (2) widely invasive FTC, invasive
sites, and/or vascular invasion are extensively present and
even grossly detected. Previous studies demonstrated that
widely invasive FTC was more likely to show recurrence and
had a poorer prognosis than minimally invasive FTC [113,
124,125].Especially,extensivevascularinvasionsigniﬁcantly
aﬀects prognosis of FTC. Therefore, it is very important to
diagnose whether an FTC is widely or minimally invasive
on pathological examination to predict patient prognosis
and select the subsequent therapy. In our series, carcinoma
recurrence rates and carcinoma death rates of patients with
widely invasive FTC were signiﬁcantly greater than those of
patients with minimally invasive FTC [113] (Figures 11(a)
and 11(b)). Since most FTC patients underwent hemithy-
roidectomy in initial surgery, we recommend completion
total thyroidectomy followed by RAI ablation for widely
invasive FTC patients but not for minimally invasive FTC
patients unless no distant metastases were detected.
3.4.2. Poor Diﬀerentiation. Involvement of PDC component
is a more signiﬁcant prognostic factor for FTC than that for
PTC. In our experience, PDC arising from FTC is generally
diagnosed as PDC on WHO classiﬁcation, because of the
presence of PDC component in the majority of the tumor.
In our series, 5-year and 10-year carcinoma recurrence rates
of FTC having PDC component were 37% and 57%, and its
carcinoma death rates were 21% and 29%, respectively [113]
(Figures 12(a) and 12(b)). On multivariate analysis, this is
the strongest prognostic factor for DFS. For CSS, this had the
second strongest prognostic impact after distant metastasis
at surgery.
3.4.3. Oxyphilic Cell Variant. Oxyphilic cell variant is a
particular type of FTC on WHO classiﬁcation. Wide cyto-
plasms with eosinophilic granules and clear nuclear bodiesJournal of Thyroid Research 13
Table 3: Risk classiﬁcation of FTC based on preoperative, intraoperative, and pathological ﬁndings.
High risk
Patients having one of the following three:
(1) patients having PDC components in the majority of carcinoma lesions,
(2) patients diagnosed with widely invasive carcinoma (extensive capsular or vascular invasion),
(3) patients having distant metastasis at diagnosis.
Intermediate risk
Patients without high-risk characteristics and having one of the following two:
(1) patients 45 yrs or older,
(2) patients having tumor >4cm.
Low risk
Patients who are not classiﬁed as high-risk or intermediate risk
Patients with extrathyroid extension and lymph-node metastasis may be classiﬁed into high and intermediate risk, respectively.
are typical ﬁndings on hematoxylin and eosin-stained tissue
sections. One study showed that most cases of oxyphilic
cell variant were RAI refractory [126]. In Europe and the
United States, many researchers have demonstrated a worse
prognosis of oxyphilic cell variant than conventional FTC
[116, 126, 127]. However, there are studies demonstrating
that prognosis of oxyphilic cell variant does not diﬀer from
[128, 129] or was even better than that of conventional
FTC [130]. In Japan, there are two studies investigating the
prognosis of oxyphilic cell variant and both demonstrated
that the prognosis of oxyphilic cell variant was similar to that
of conventional FTC [113, 131]. It is, therefore, not evident
that oxyphilic cell variant shows an aggressive behavior in
Japan. The prevalence of oxyphilic cell variant was 13% in
our series [113], which is similar to that in the United States
[116].
3.4.4. Pathological Lymph-Node Metastasis. Lymph-node
dissection is not performed for surgery for patients unless
metastatic nodes are clinically detected or cytological exam-
ination suggests high-grade malignancy such as PDC. In
our series, 11 of 334 patients (3%) had pathologically
diagnosed lymph-node metastasis and 10 of these patients
were diagnosed as having widely invasive FTC or PDC as
indicated above [113]. During postoperative followup, 10
patients (3%) showed recurrence to the regional lymph
nodes after surgery and 8 of these were widely invasive
carcinoma or included PDC components in specimens in
initial surgery. Therefore, although rare, the presence of
lymph-node metastasis reﬂects aggressive behavior of FTC.
A report form Germany also demonstrated the prognostic
impact of lymph-node metastasis of FTC and recommended
extensive lymph-node dissection, including MND, for FTC
demonstrating a large tumor and/or extrathyroid extension
[120].
3.5. Discussion and Summary. In contrast to PTC, FTC can
rarely be diagnosed on preoperative examinations, includ-
ing ultrasonography and cytology. The most signiﬁcant
prognostic factor was the presence of distant metastasis at
surgery. Apart from that, pathological ﬁndings such as the
involvement of PDC components and widely invasive lesions
were signiﬁcant prognostic factors. Although oxyphilic cell
variant did not aﬀect prognosis in studies from Japan,
many studies from Western countries indicated that this
variant is a sign of aggressive behavior. Taken together,
pathological evaluation of FTC is very important to predict
patient prognosis and select the therapeutic strategy such
as whether completion total thyroidectomy should be per-
formed. Patient age, gender, and tumor size have a moderate
prognostic impact. Table 3 summarizes the risk classiﬁcation
of FTC. In addition, extrathyroid extension and pathological
lymph node metastasis are rare events in FTC, but these
ﬁndings are much more likely detected in patients showing
an aggressive histology. Although these ﬁndings can be signs
of aggressive behavior, it remains unclear whether they are
independent prognostic factors.
4. Conclusions
The signiﬁcance of preoperative evaluation and patho-
logical examination diﬀers between PTC and FTC. For
PTC, preoperative ﬁndings on imaging studies and intraop-
erative ﬁndings are quite important to evaluate biological
behavior, including prognosis, and therapeutic strategies
can be established for most patients at that time. Distant
metastasis at surgery, extrathyroid extension, large lymph-
node metastasis, and extranodal tumor extension are signiﬁ-
cant prognostic factors and extensive surgery and adjuvant
therapy with careful followup are mandatory for patients
with such characteristics.
In contrast, postoperative pathological examination has
a signiﬁcant value not only for diagnosis of FTC but also
for evaluating biological characteristics. Similar to PTC,
distant metastasis at surgery is the strongest prognostic
factor,butpathologicalﬁndingssuchasgradeofinvasiveness
and carcinoma diﬀerentiation are also very important to
evaluate its biological behavior. Such pathological ﬁndings
are essential to decide whether to perform further therapies
such as completion total thyroidectomy with RAI therapy for
FTC.14 Journal of Thyroid Research
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